Search our Database of Scientific Publications and Authors

I’m looking for a

    803 results match your criteria Lupus Erythematosus Subacute Cutaneous

    1 OF 17

    Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90 Patients at Mayo Clinic, 1996-2011.
    Mayo Clin Proc 2017 Feb 6. Epub 2017 Feb 6.
    Department of Dermatology, Mayo Clinic, Rochester, MN. Electronic address:
    Objective: To characterize the clinical presentation, laboratory studies, disease associations, and treatments of subacute cutaneous lupus erythematosus (SCLE).

    Patients And Methods: A retrospective review of 90 patients with SCLE at Mayo Clinic from January 1, 1996, through October 28, 2011, was performed.

    Results: The mean patient age at diagnosis was 61 years; 64 patients (71%) were women, and 11 cases (12%) were drug induced (1996-2000, no drug-induced cases; 2001-2005, 2 cases; 2006-2011, 9 cases). Read More

    Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
    Br J Dermatol 2017 Jan 23. Epub 2017 Jan 23.
    Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Université de Strasbourg, F-67000, Strasbourg, France.
    Background: The antimalarials (AMs) hydroxychloroquine (HCQ) or chloroquine (CQ) have demonstrated variable cutaneous response rates in Cutaneous Lupus Erythematosus (CLE).

    Objectives: We sought to assess the global cutaneous response rate to HCQ and CQ, with respect to CLE subtypes, based on previously published studies.

    Methods: We performed a systematic review and meta-analysis of studies published in MEDLINE, Embase, Cochrane library between 1965 and December 2015. Read More

    Voriconazole-Induced Subacute Cutaneous Lupus Erythematosus in an Adult With Aspergillosis.
    Skinmed 2016 1;14(6):461-463. Epub 2016 Dec 1.
    Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN.
    A 59-year-old man was treated with voriconazole for chronic invasive aspergillosis and who subsequently developed subacute cutaneous lupus erythematosus (SCLE). The patient presented with a 6-week history of multiple erythematous papulosquamous lesions on his chest, upper and lower extremities, and back (Figure 1). They were nonpruritic and nonpainful. Read More

    Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy.
    J Clin Diagn Res 2016 Oct 1;10(10):OD06-OD07. Epub 2016 Oct 1.
    Intern, Department of Medicine, Pt. BD Sharma PGIMS , Rohtak, Haryana, India .
    Leflunomide is an immunomodulatory drug exhibiting anti-inflammatory, anti-proliferative and immunosuppressive effects. It has been widely used for treatment of active rheumatoid arthritis. Despite its good safety profile cutaneous side effects like alopecia, eczema, pruritis and dry skin have been reported with Leflunomide use. Read More

    Subacute cutaneous lupus erythematosus inducing unilateral sensorimotor neuropathy.
    Rheumatol Int 2016 Nov 25. Epub 2016 Nov 25.
    Department of Internal Medicine, Nicosia General Hospital, Nicosia, Cyprus.
    We describe the case of a 32-year-old male with previous history of subacute cutaneous lupus erythematosus (SCLE) who presented with arthritis followed by a unilateral lower-limb sensorimotor impairment, without biochemical or immunological marker abnormalities. Our patient currently satisfies only three of the systemic lupus international collaborating clinics criteria. Management of such patients is challenging due to lack of examples in the literature, with this case being the first described where a seronegative patient with SCLE demonstrated neurological involvement. Read More

    Drug-induced cutaneous lupus erythematosus: 88 new cases.
    Eur J Dermatol 2017 Feb;27(1):28-33
    Department of Dermatology and Allergy Centre, Odense University Hospital, DK-5000, Odense C, Denmark.
    Background: An increasing number of drugs have been linked to drug-induced subacute cutaneous lupus erythematosus (DI-SCLE). The recognition and management of DI-SCLE can be challenging, as the condition may be triggered by different classes of drugs after variable lengths of time.

    Objectives: To determine the proportion of patients with cutaneous lupus erythematosus (CLE) whose drugs are an inducing or aggravating factor. Read More

    Cutaneous metastasis of inflammatory breast carcinoma mimicking an erythema annulare centrifugum: a sign of locally recurrent cancer.
    Clin Exp Dermatol 2016 Dec 20;41(8):906-910. Epub 2016 Oct 20.
    Department of Oncology, Hospital Casa de Salud, Valencia, Spain.
    Erythema annulare centrifugum (EAC) is a clinical reaction pattern that includes lupus erythematosus, spongiotic dermatitis (particularly pityriasis rosea), pseudolymphoma and cutaneous B-cell lymphoma. However, it can be the result of cutaneous metastasis by an internal carcinoma. We present the case of a 38-year-old woman with bilateral inflammatory breast cancer following multimodal therapy. Read More

    Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop.
    J Invest Dermatol 2017 Jan 16;137(1):115-122. Epub 2016 Sep 16.
    Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Electronic address:
    Cutaneous lupus erythematosus is a disfiguring and common manifestation in systemic lupus erythematosus, and the etiology of this predisposition for cutaneous inflammation is unknown. Here, we sought to examine the keratinocyte as an important source of IL-6 and define the mechanism for its increased production in cutaneous lupus erythematosus. Evaluation of discoid and subacute cutaneous lupus erythematosus lesions showed significant epidermal up-regulation of IL-6 compared with control via real-time PCR and immunohistochemistry. Read More

    Anastrozole-induced subacute cutaneous lupus erythematosus.
    Cutis 2016 Aug;98(2):E22-6
    Northwell Department of Dermatology, Hofstra-Northwell School of Medicine, Hempstead, New York, USA.
    Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) has been associated with numerous drugs, but there are limited reports of its association with aromatase inhibitor anastrozole. We report the case of a patient undergoing treatment with anastrozole for breast cancer who presented with clinical, serological, and histological evidence consistent with DI-SCLE. Her condition quickly began to improve after the use of anastrozole was discontinued and hydroxychloroquine therapy was initiated. Read More

    Dermoscopy in General Dermatology: A Practical Overview.
    Dermatol Ther (Heidelb) 2016 Dec 9;6(4):471-507. Epub 2016 Sep 9.
    Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine, Udine, Italy.
    Over the last few years, dermoscopy has been shown to be a useful tool in assisting the noninvasive diagnosis of various general dermatological disorders. In this article, we sought to provide an up-to-date practical overview on the use of dermoscopy in general dermatology by analysing the dermoscopic differential diagnosis of relatively common dermatological disorders grouped according to their clinical presentation, i.e. Read More

    Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters.
    J Eur Acad Dermatol Venereol 2016 Aug 24. Epub 2016 Aug 24.
    Department of Dermatovenereology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
    Background: Dysregulation of apoptosis has an important role in the induction of autoimmunity.

    Objective: To evaluate the influence of keratinocyte apoptosis and deoxyribonuclease I (DNase I) activity on the clinical and immunoserological parameters of cutaneous lupus erythematosus (CLE).

    Methods: We studied 69 CLE patients (39 with discoid LE (DLE), 12 with subacute CLE (SCLE), 12 with acute and 6 with intermittent CLE). Read More

    Cutaneous characteristics and association with antinuclear antibodies in 402 patients with different subtypes of lupus erythematosus.
    J Eur Acad Dermatol Venereol 2016 Dec 19;30(12):2097-2104. Epub 2016 Jul 19.
    Connective tissue disease research unit of the Department of Dermatology, Venereology, and Allergology, Ruhr-University Bochum, Bochum, Germany.
    Background: Lupus erythematosus (LE) is an autoimmune disease characterized by a heterogeneous spectrum of skin manifestations and organ affection, and is frequently associated with serum autoantibodies, which mostly remain positive through the course of the disease. The classification of LE is still a controversial topic.

    Objectives: To examine the prevalence and long-term course of autoantibodies in patients with cutaneous LE (CLE) and/or systemic LE (SLE) treated in the outpatient clinic for connective tissue diseases of the department of Dermatology in Bochum, Germany. Read More

    Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.
    Drugs Real World Outcomes 2016 Jun 29;3(2):145-154. Epub 2016 Mar 29.
    The Ohio State University Wexner Medical Center, 410 W 10th Ave, Columbus, OH 43210 USA.
    Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease that may be induced by proton pump inhibitors (PPIs) in at-risk populations. The US FDA does not recognize SCLE as an adverse event associated with PPIs. We queried the FDA Adverse Event Reporting System database, which contains adverse event case reports submitted by the public as well as by industry, and analyzed the data to quantify passive pharmacovigilance signals for SCLE associated with PPIs. Read More

    Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Arthritis Care Res (Hoboken) 2017 Jan 18;69(1):115-123. Epub 2016 Nov 18.
    University of Padova, Padova, Italy.
    Objective: To investigate effectiveness and safety of belimumab in patients with active systemic lupus erythematosus (SLE) in a clinical practice setting.

    Methods: Sixty-seven patients with active SLE, mean ± SD age 39.3 ± 10. Read More

    Subacute cutaneous lupus erythematosus.
    J R Army Med Corps 2016 Jun 9. Epub 2016 Jun 9.
    Department of Cellular and Anatomical Pathology, Derriford Hospital, Plymouth, UK.
    A 31-year-old female soldier developed subacute cutaneous lupus erythematosus, which remained undiagnosed for 4 years. Referral to dermatology and a punch biopsy confirmed the diagnosis and effective treatment was instituted. The presence of an unresolving annular rash in light-exposed areas, especially in a young woman, should prompt thorough investigation and referral if necessary. Read More

    Advances in the treatment of cutaneous lupus erythematosus.
    Lupus 2016 Jul;25(8):830-7
    Department of Dermatology, University of Bonn, Germany.
    Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used "off-label", primarily based on open-label studies, case series, retrospective analyses, and expert opinions. Read More

    Toxic Epidermal Necrolysis-Like Cutaneous Lupus in Pediatric Patients: A Case Series and Review.
    Pediatrics 2016 Jun;137(6)
    Division of Pediatric Dermatology, Departments of Dermatology and Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin;
    Bullous eruptions in patients with underlying systemic lupus erythematosus (LE) can mimic toxic-epidermal necrolysis (TEN), a rapidly progressive mucocutaneous reaction usually associated with medication use. Differentiating between classic drug-induced TEN and TEN-like cutaneous LE is important but difficult. We report a series of 3 patients with pediatric systemic LE who were admitted with severe worsening of skin disease resembling TEN. Read More

    Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand.
    Lupus 2016 Nov 11;25(13):1497-1502. Epub 2016 Jul 11.
    2 Department of Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand.
    Background The prevalence and variation by ethnicity of cutaneous lupus in New Zealand is not known. Therefore, a cross-sectional study to determine the prevalence and variation by ethnicity of cutaneous lupus in the ethnically diverse community of South Auckland, New Zealand, was undertaken. Methods Multiple sources were examined to determine the prevalence of acute cutaneous lupus erythematosus, subacute cutaneous erythematosus and discoid lupus erythematosus. Read More

    Cytokines and Effector/Regulatory Cells Characterization in the Physiopathology of Cutaneous Lupus Erythematous: A Cross-Sectional Study.
    Mediators Inflamm 2016 6;2016:7074829. Epub 2016 Mar 6.
    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Vasco de Quiroga No. 15, Colonia Belisario Dominguez Sección XVI, 14080 Mexico City, DF, Mexico.
    We compared the presence of diverse cytokines and regulatory T and B cells in skin biopsies of discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE). We included 19 patients with DLE, 13 with SCLE, 8 healthy controls, and 5 patients with hypertrophic scars. We assessed the CLASI activity score. Read More

    Mast cells in systemic and cutaneous lupus erythematosus.
    Pol J Pathol 2015 Dec;66(4):397-402
    Krzysztof Okoń, Department of Pathomorphology, Jagiellonian University Collegium Medicum, Grzegórzecka 16, 31-531 Krakow, Poland, e-mail:
    Mast cells (MCs) are known to be regulators of inflammation and immunity, due to the released mediators and expressed cell surface molecules. Lupus erythematosus (LE) is a group of diseases which can be systemic or limited to the skin. Due to the fact that cytokines and chemokines produced by inflammatory cells contribute to the pathogenesis of LE, we quantified the number of mast cells present in the skin. Read More

    Cutaneous Lupus Erythematosus in Children: Experience from a Tertiary Care Pediatric Dermatology Clinic.
    Pediatr Dermatol 2016 Mar-Apr;33(2):200-8
    As'ad Al-Hamad Dermatology Center, Al-Sabah Hospital, Kuwait City, Kuwait.
    Background/objectives: The manifestations of cutaneous lupus erythematosus (CLE) and their relevance to systemic disease are well characterized in adults, but data are limited in children. The objective of the current study was to examine the spectrum of CLE and its relationship to systemic disease in children from a tertiary care pediatric dermatology clinic.

    Materials And Methods: An analysis of 26 children with CLE registered consecutively over 14 years was performed. Read More

    Clinical characteristics of cutaneous lupus erythematosus.
    Postepy Dermatol Alergol 2016 Feb 29;33(1):13-7. Epub 2016 Feb 29.
    Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
    Introduction: Lupus erythematosus (LE) shows a wide variety of clinical manifestations, skin involvement being one of the most important.

    Aim: To analyze the clinical presentation of cutaneous variants of lupus erythematosus in terms of skin lesion spectrum and extracutaneous involvement.

    Material And Methods: A total of 64 patients with cutaneous LE (CLE) were included. Read More

    Microarray study reveals a transforming growth factor-β-dependent mechanism of fibrosis in discoid lupus erythematosus.
    Br J Dermatol 2016 Aug 29;175(2):302-13. Epub 2016 May 29.
    Department of Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
    Background: Discoid lupus erythematosus (DLE) is characterized by scarring lesions that develop and perpetuate fibrotic lesions. These are not observed in subacute cutaneous lupus erythematosus (SCLE). The pathophysiological basis of this is currently unknown. Read More

    Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report.
    Chemotherapy 2016 1;61(5):236-9. Epub 2016 Mar 1.
    Subacute cutaneous lupus erythematosus (SCLE) is a rare eruption related to several pharmacological and chemotherapy agents. We present a 63-year-old female with recurrent epithelial ovarian cancer who developed SCLE after administration of gemcitabine. Following discontinuation of gemcitabine and after oral steroid treatment, all skin lesions disappeared. Read More

    Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE).
    J Am Acad Dermatol 2016 May 18;74(5):862-9. Epub 2016 Feb 18.
    Corporal Michael J. Crescenz Philadelphia Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address:
    Background: Approximately 50% of patients with subacute cutaneous lupus erythematosus (SCLE) meet criteria for systemic lupus erythematosus (SLE). The Systemic Lupus International Collaborating Clinics (SLICC) developed new SLE criteria to improve the American College of Rheumatology (ACR) criteria but the SLICC criteria have not been evaluated in patients with SCLE.

    Objective: We sought to determine how patients with SCLE/SLE meet the ACR and SLICC criteria to compare the 2 sets of criteria. Read More

    Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
    Int J Dermatol 2016 Aug 12;55(8):e431-9. Epub 2016 Feb 12.
    Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
    Background: Published case series describe lenalidomide as an effective treatment of refractory cutaneous lupus erythematosus (CLE).

    Objectives: The present study aimed to further characterize lenalidomide use in the treatment of CLE.

    Methods: A retrospective review of patients treated with lenalidomide for CLE from January 1, 2000, to December 17, 2014, was conducted. Read More

    The high incidence of anti-Ro/SSA and anti-p200 antibodies in female patients with connective tissue diseases confirms the importance of screening for congenital heart block-associated autoantibodies during pregnancy.
    Arch Dermatol Res 2016 Mar 1;308(2):139-43. Epub 2016 Feb 1.
    Section of Dermatology, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, 16132, Genoa, Italy.
    It is known that anti-Ro/SSA positivity leads to higher risk of miscarriage and fetal cardiac malformations. Particularly, anti-p200 antibodies against a finer specificity of the Ro/SSA antigen, have been associated with congenital heart block. The aim of the study was to assess the frequency of anti-p200 among female patients with different connective tissue diseases and, among these, the relevance of anti-p200 values in patients with cutaneous diseases compared to systemic diseases. Read More

    Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management.
    Curr Allergy Asthma Rep 2016 Mar;16(3):17
    Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, USA.
    PPIs are among the most commonly administered medications in the USA and are generally well tolerated. Immediate and delayed immune-mediated hypersensitivity reactions are rare but increasingly recognized adverse effects of proton pump inhibitors (PPIs). Immediate hypersensitivity reactions can occur due to IgE-mediated hypersensitivity to PPIs and can be evaluated by immediate hypersensitivity skin testing and oral provocation challenge testing. Read More

    Homocysteine serum levels are increased and correlate with disease severity in patients with lupus erythematosus.
    Clin Exp Rheumatol 2016 Jan-Feb;34(1):76-81. Epub 2016 Jan 8.
    Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Italy.
    Objectives: To determine homocysteine (Hcy) serum levels in patients with cutaneous lupus erythematosus (CLE) and a possible correlation with the disease activity.

    Methods: Ninety-three patients with LE and 30 healthy controls were included in the study. For each patient, disease activity was calculated and plasma levels of Hcy was measured by enzymatic colorimetric assay. Read More

    Blisters and Loss of Epidermis in Patients With Lupus Erythematosus: A Clinicopathological Study of 22 Patients.
    Medicine (Baltimore) 2015 Nov;94(46):e2102
    From the Faculté de Médecine, Université de Strasbourg; Clinique Dermatologique, Hôpitaux Universitaires de Strasbourg, Strasbourg (CM-D, DL); Faculté de Médecine, Université de Montpellier; Département de Dermatologie, Hôpital Saint Eloi, CHRU Montpellier, Montpellier (DB); Faculté de Médecine, Université Pierre-et-Marie-Curie Paris-VI, Service de Dermatologie Hôpital Tenon, Paris (CF); Faculté de Médecine, Université Claude Bernard Lyon 1, Service de Dermatologie, CHU Lyon Sud, Pierre-Bénite (NP, SD); and Service de Dermatologie-Médecine interne, CHU de Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe, (NC) France.
    The nosology of bullous lesions or equivalents (vesicles, erosions, and crusts) in patients with lupus erythematosus (LE) is rarely addressed.The primary aim of this study was to draw up a precise phenotypic inventory of such skin lesions; the secondary objective was to assess a potential relationship between the different types of loss of epidermis and extracutaneous lupus manifestations.We conducted a retrospective multicenter study including 22 patients with definite LE and bullous lesions or equivalents. Read More

    Kikuchi Disease-Like Inflammatory Pattern in Cutaneous Inflammatory Infiltrates Without Lymph Node Involvement: A New Clue for the Diagnosis of Lupus?
    Medicine (Baltimore) 2015 Nov;94(46):e2065
    From the Department of Internal Medicine (L-HT, BG, NL); Department of Dermatology (SI-H-O, PW, OC); Department of Pathology (NO), AP-HP, CHU Henri-Mondor, UPEC University; EA EpiDermE (Epidemiology in Dermatology and Evaluation of Therapeutics), INSERM, CIC 1430 (SI-H-O, PW, OC); INSERM U955 team 9, Créteil (NO); C. Cap Orléans Laboratory, Orléans (LR, JK); and Department of Dermatology, CHG de Dreux, Dreux, France (VP).
    Kikuchi-Fujimoto disease (KFD) is a rare and benign disorder that usually occurs in young adults with enlarged lymph nodes containing infiltrate of cytotoxic T cells and nuclear debris. It can be a manifestation of systemic lupus erythematosus (SLE) although the strength of this association has varied among studies. Although specific KFD cutaneous lesions are well described, pure cutaneous lesions have never been reported. Read More

    Drug-Induced Subacute Cutaneous Lupus Erythematosus in a Patient Receiving Therapy for Chronic Hepatitis C.
    Am J Ther 2016 Nov/Dec;23(6):e1965-e1967
    Department of Medicine, New York Medical College, Metropolitan Hospital Center, New York, NY.
    Hepatitis C infection and its treatment have been associated with extrahepatic manifestations, including different skin conditions. Over the past decades, a greater number of drugs have been implicated as triggers for drug-induced subacute cutaneous lupus erythematosus. We report a case of a 42-year-old Hispanic man who developed a forehead violaceous rash during treatment with pegylated interferon alpha-2a as part of his therapy against hepatitis C infection that subsequently resulted to be subacute cutaneous lupus erythematosus. Read More

    Two cases of annular erythema without bullous lesions by autoimmune blistering diseases.
    Mod Rheumatol 2015 Oct 19:1-3. Epub 2015 Oct 19.
    a Department of Dermatology , Shiga University of Medical Science , Setatsukinowa , Otsu , Shiga , Japan.
    Although annular erythema is usually observed as one of the cutaneous manifestations of Sjögren's syndrome or subacute cutaneous lupus erythematosus, autoimmune blistering diseases also present with annular erythema. However, bullous lesions are not always found, and there is a rare type without bullous lesions. We present two cases of autoimmune blistering diseases showing annular erythema without bullous lesions. Read More

    Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.
    Clin Exp Immunol 2016 Feb 9;183(2):258-70. Epub 2015 Nov 9.
    PharmaTherapeutics Clinical Research and Development, Pfizer, Cambridge, MA, USA.
    This study's objective was to assess the effects of PD-0360324, a fully human immunoglobulin G2 monoclonal antibody against macrophage colony-stimulating factor in cutaneous lupus erythematosus (CLE). Patients with active subacute CLE or discoid lupus erythematosus were randomized to receive 100 or 150 mg PD-0360324 or placebo via intravenous infusion every 2 weeks for 3 months. Blood and urine samples were obtained pre- and post-treatment to analyse pharmacokinetics and pharmacodynamic changes in CD14(+) CD16(+) monocytes, urinary N-terminal telopeptide (uNTX), alanine/aspartate aminotransferases (ALT/AST) and creatine kinase (CK); tissue biopsy samples were taken to evaluate macrophage populations and T cells using immunohistochemistry. Read More

    Apoptosis in chronic cutaneous lupus erythematosus, discoid lupus, and lupus profundus.
    Int J Clin Exp Pathol 2015 1;8(6):7260-5. Epub 2015 Jun 1.
    Laboratory of Immunology and Molecular Biology, UABE, Universidad Autónoma de Zacatecas Zacatecas, Zac, Mexico.
    Introduction: Lupus erythematosus is a multisystemic disease that is characterized by autoantibody production and immune complex deposition in such tissues as the mucosa, joints, the central nervous system, and skin. Cutaneous lupus erythematosus is categorized as acute, subacute, and chronic. Chronic cutaneous lupus erythematosus comprises discoid lupus erythematosus (DLE) and lupus profundus (LP). Read More

    Subacute cutaneous lupus erythematosus starting as linear lupus erythematosus.
    Int J Dermatol 2016 Feb 31;55(2):173-6. Epub 2015 Jul 31.
    Department of Dermatology, General University Hospital of Alicante, Alicante, Spain.
    Background: Cutaneous lupus in childhood is usually associated with systemic lupus erythematosus (LE). Linear cutaneous LE (LCLE) is an unusual presentation mostly seen in children and young adults.

    Methods: We report a rare case of cutaneous subacute LE with a segmentary pattern following the lines of Blaschko in an 18-month-old girl with a 2-month history of persistent, linear, asymptomatic, erythematous lesions along the right arm. Read More

    Imiquimod-induced subacute cutaneous lupus erythematosus-like changes.
    Cutis 2015 Jun;95(6):349-51
    Palo Alto Medical Foundation, 701 E El Camino Real, Mountain View, CA 94306, USA.
    Imiquimod is a topical immunomodulator used to treat genital warts and cutaneous malignancies that exerts its effects via induction of proinflammatory cytokines through activation of toll-like receptor (TLR) 7. Although subacute cutaneous lupus erythematosus (SCLE) has been reported in association with multiple systemic medications, SCLE in patients treated with topical agents has not been widely reported. We report the case of a 50-year-old woman with local induction of lesions that clinically and histologically resembled SCLE following treatment with topical imiquimod. Read More

    Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses.
    Dermatol Pract Concept 2015 Apr 30;5(2):121-4. Epub 2015 Apr 30.
    Department of Dermatology, University of California San Diego, San Diego, CA, USA.
    Background: Taxanes [paclitaxel, nab-paclitaxel (Abraxane, Celgene Corp, USA), and docetaxel]-used in the treatment of lung, breast, and head and neck cancers-have been associated with cutaneous adverse effects, including photodermatoses.

    Purpose: We describe a woman with non-small cell lung cancer who developed a photodistributed dermatitis associated with her nab-paclitaxel therapy and review photodermatoses in patients receiving taxanes.

    Materials And Methods: The features of a woman with a nab-paclitaxel-associated photodistributed dermatitis are presented and the literature on nab-paclitaxel-associated photosensitivity is reviewed. Read More

    Proton pump inhibitor-induced Sweet's syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer.
    Dermatol Pract Concept 2015 Apr 30;5(2):113-9. Epub 2015 Apr 30.
    Department of Dermatology, University of California San Diego, San Diego, CA, USA.
    Background: Sweet's syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug. Proton pump inhibitors selectively inhibit gastric parietal cell H+-K+-adenosine triphosphatase and are most commonly used for the treatment of gastroesophageal reflux disease.

    Purpose: Proton pump inhibitor-associated Sweet's syndrome is described in a woman with recurrent breast cancer. Read More

    1 OF 17